{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:07:17Z","timestamp":1790687237378,"version":"4.1.0"},"reference-count":27,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>(1) Background: To investigate the real-world effectiveness and safety profile of nusinersen in Croatian paediatric and adult spinal muscular atrophy (SMA) patients. (2) Methods: A retrospective and anonymous collection of relevant demographic and clinical data for all Croatian SMA patients treated with nusinersen and reimbursed by the Croatian Health Insurance Fund (CHIF) between April 2018 and February 2022 was performed through searching the CHIF database and studying the associated reimbursement documentation. All patients who received at least one dose of nusinersen were included in the baseline clinical-demographic overview and safety analysis, whereas only subjects who had completed six doses were included in the effectiveness analysis. (3) Results: Fifty-two patients [61.5% male; median age 13.4 (0.1\u201351.1) yr.] received nusinersen treatment. In SMA type 1 and type 3 paediatric patients, statistically significant motor function improvement (CHOP INTEND 10.8 \u00b1 10.3 vs. 20.0 \u00b1 15.8, p = 0.003; HFMSE 49.6 \u00b1 7.9 vs. 53.1 \u00b1 7.7, p = 0.008; respectively) was achieved immediately after 4 loading doses of nusinersen and remained statistically significant onwards. Average improvements in HFMSE motor performance in SMA type 2 patients after four, five, and six doses of nusinersen were +6.0, +10.5, and +11.0 points, respectively. In SMA type 3 adult patients, no significant improvement in RHS motor performance or the 6-Minute Walk Test (MWT) was demonstrated. During the study period, 437 doses were administered without any new safety concerns appearing. (4) Conclusions: Our RWD findings indicate that nusinersen is an effective and safe treatment in a heterogeneous group of paediatric patients with all types of SMA; however, no significant benefit (but only RHS and 6MWT maintenance) was demonstrated in SMA type 3 patients who started nusinersen after &gt;18 years of age.<\/jats:p>","DOI":"10.3390\/jcm12082839","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T01:35:00Z","timestamp":1681349700000},"page":"2839","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Effectiveness of Nusinersen in Type 1, 2 and 3 Spinal Muscular Atrophy: Croatian Real-World Data"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7848-6600","authenticated-orcid":false,"given":"Andrej","family":"Belan\u010di\u0107","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, Clinical Hospital Centre Rijeka, 51000 Rijeka, Croatia"},{"name":"Department of Basic and Clinical Pharmacology with Toxicology, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6764-3436","authenticated-orcid":false,"given":"Tea","family":"Strbad","sequence":"additional","affiliation":[{"name":"Croatian Health Insurance Fund, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Ku\u010dan \u0160tigli\u0107","sequence":"additional","affiliation":[{"name":"Primorje-Gorski Kotar County Community Health Centre, 51000 Rijeka, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6295-6580","authenticated-orcid":false,"given":"Dinko","family":"Vitezi\u0107","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Clinical Hospital Centre Rijeka, 51000 Rijeka, Croatia"},{"name":"Department of Basic and Clinical Pharmacology with Toxicology, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.pcl.2015.03.010","article-title":"Spinal muscular atrophies","volume":"62","author":"Darras","year":"2015","journal-title":"Pediatr. Clin. N. Am."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy\u2014A literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1038\/s41598-023-30449-7","article-title":"A comprehensive overview of SMN and NAIP copy numbers in Iranian SMA patients","volume":"13","author":"Savad","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s43042-019-0044-z","article-title":"Genetic pattern of SMN1, SMN2, and NAIP genes in prognosis of SMA patients","volume":"21","author":"Hassan","year":"2020","journal-title":"Egypt. J. Med. Hum. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3988\/jcn.2017.13.1.27","article-title":"Genotype-Phenotype Correlation of SMN1 and NAIP Deletions in Korean Patients with Spinal Muscular Atrophy","volume":"13","author":"Ahn","year":"2017","journal-title":"J. Clin. Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Chen, T.H. (2020). New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093297"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/gt.2017.52","article-title":"The clinical landscape for SMA in a new therapeutic era","volume":"24","author":"Talbot","year":"2017","journal-title":"Gene Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics","volume":"28","author":"Finkel","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/dmcn.14027","article-title":"Nusinersen treatment of spinal muscular atrophy: Current knowledge and existing gaps","volume":"61","author":"Gidaro","year":"2019","journal-title":"Dev. Med. Child. Neurol."},{"key":"ref_11","unstructured":"(2022, November 25). European Medicines Agency Spinraza: EPAR\u2013Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/spinraza-epar-product-information_en.pdf."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejpn.2020.05.002","article-title":"Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients","volume":"27","author":"Gergely","year":"2020","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_15","unstructured":"U.S. Food & Drug Administration (2022, December 10). Framework for FDA\u2019s Real-World Evidence Program, Available online: https:\/\/www.fda.gov\/media\/120060\/download."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpn.2020.11.004","article-title":"Children and young adults with spinal muscular atrophy treated with nusinersen","volume":"30","author":"Osredkar","year":"2021","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"289","DOI":"10.5603\/PJNNS.a2021.0020","article-title":"Nusinersen treatment of Spinal Muscular Atrophy Type 1\u2014Results of expanded access programme in Poland","volume":"55","author":"Modrzejewska","year":"2021","journal-title":"Neurol. Neurochir. Pol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.nmd.2022.02.001","article-title":"Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland","volume":"32","author":"Tscherter","year":"2022","journal-title":"Neuromuscul. Disord."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3233\/JND-180315","article-title":"Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany","volume":"5","author":"Pechmann","year":"2018","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/ana.25533","article-title":"Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data","volume":"86","author":"Pane","year":"2019","journal-title":"Ann. Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.nmd.2021.03.007","article-title":"Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go","volume":"31","author":"Dangouloff","year":"2021","journal-title":"Neuromuscul. Disord."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/jnnp-2021-326344","article-title":"Newborn screening for spinal muscular atrophy with disease-modifying therapies: A cost-effectiveness analysis","volume":"92","author":"Shih","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"P1.6-063","DOI":"10.1212\/WNL.0000000000007527","article-title":"Interim Report on the Safety and Efficacy of Longer-term Treatment with Nusinersen in Later-onset Spinal Muscular Atrophy (SMA): Results from the SHINE Study (P1.6-063)","volume":"92","author":"Darras","year":"2019","journal-title":"Neurology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/acn3.51514","article-title":"Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy","volume":"9","author":"Pane","year":"2022","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s13023-021-02065-z","article-title":"Motor function in type 2 and 3 SMA patients treated with Nusinersen: A critical review and meta-analysis","volume":"16","author":"Coratti","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3233\/JND-190416","article-title":"Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3\u2014A Prospective Observational Study","volume":"6","author":"Walter","year":"2019","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/cpt.2766","article-title":"Contribution of Real-World Evidence in European Medicines Agency\u2019s Regulatory Decision Making","volume":"113","author":"Bakker","year":"2022","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/8\/2839\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:15:08Z","timestamp":1760123708000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/8\/2839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,13]]},"references-count":27,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["jcm12082839"],"URL":"https:\/\/doi.org\/10.3390\/jcm12082839","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,13]]}}}